XML 25 R13.htm IDEA: XBRL DOCUMENT
v3.25.3

Capital Stock, Stock Plans and Stock-Based Compensation | 9 Months Ended
--- | ---
Sep. 30, 2025
Share-Based Payment Arrangement [Abstract] |
Capital Stock, Stock Plans and Stock-Based Compensation |
6. | Capital Stock, Stock Plans and Stock-Based Compensation
The Company has certain stock option plans under which it may award incentive stock options (“ISOs”) and/or non-qualified stock options (“NQSOs”) to employees, officers, outside directors, and outside consultants. In connection with the appointment of Mr. Troy Eshleman to the position of Chief Operating Officer (“COO”) by the Company’s Board of Directors (the “Board”) on January 23, 2025, the Company granted to Mr. Eshleman an ISO for the purchase, under the Company’s 2017 Stock Option Plan (the “2017 Plan”), of up to 50,000 shares of the Company’s common stock, $.001 (the “Common Stock”). The ISO has a six-year6 term and vests at 20% per year over a five-year5 period, commencing on the first anniversary of the grant date. The exercise price of the ISO is $10.70 per share, which equals the closing price of the Company’s Common Stock as quoted on NASDAQ on the grant date. On July 24, 2025, the Company issued a NQSO to each of the Company’s seven reelected outside (non-management) directors for the purchase, under the Company’s 2003 Outside Directors Stock Plan (the “2003 Plan”), of up to 10,000 shares of the Company’s Common Stock. Dr. Louis Centofanti and Mark Duff, each an executive officer of the Company as well as a director, were not eligible to receive an option under the 2003 Plan. Each NQSO granted has a four-year term and vests at 25% per year over a four-year4 period, commencing on the first anniversary of the grant date. The exercise price of each NQSO is $12.23 per share, which was equal to the fair market value of the Company’s Common Stock on the day preceding the grant date, in accordance with the 2003 Plan. The following table summarizes stock-based compensation recognized for the three and nine months ended September 30, 2025, and 2024 for our employee and director stock options. Schedule of Share-based Compensation, Allocation of Recognized Period Costs
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three Months Ended |  |  | Nine Months Ended |
Stock Options |  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Employee Stock Options |  | $ | 108,000 |  |  | $ | 96,000 |  |  | $ | 311,000 |  |  | $ | 259,000 |
Director Stock Options |  |  | 107,000 |  |  |  | 86,000 |  |  |  | 286,000 |  |  |  | 207,000 |
Total |  | $ | 215,000 |  |  | $ | 182,000 |  |  | $ | 597,000 |  |  | $ | 466,000 |
As of September 30, 2025, the Company had approximately $2,131,000 of total unrecognized compensation costs related to unvested options for employee and directors. The weighted average period over which the unrecognized compensation costs are expected to be recognized is approximately 3.0 years. The summary of the Company’s stock option plans as of September 30, 2025, and September 30, 2024, and changes during the periods then ended, are presented below. The Company’s plans consist of the 2017 Plan and the 2003 Plan: Schedule of Stock Options Roll Forward
|  | Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (years) |  |  | Aggregate Intrinsic Value (5) |
Options outstanding January 1, 2025 |  |  | 1,000,900 |  |  | $ | 6.18 |  |  |  |  |  |  |  | - |
Granted |  |  | 120,000 |  |  | $ | 11.59 |  |  |  |  |  |  |  |  |
Exercised |  |  | (88,700 | ) |  | $ | 4.11 |  |  |  |  |  |  | $ | 586,180 |
Forfeited |  |  | (17,000 | ) |  | $ | 8.72 |  |  |  |  |  |  |  |  |
Options outstanding end of period (1) |  |  | 1,015,200 |  |  | $ | 6.96 |  |  |  | 4.7 |  |  | $ | 3,367,934 |
Options exercisable at September 30, 2025(2) |  |  | 455,200 |  |  | $ | 6.50 |  |  |  | 4.5 |  |  | $ | 1,809,173 |
|  | Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (years) |  |  | Aggregate Intrinsic Value (5) |
Options outstanding January 1, 2024 |  |  | 994,500 |  |  | $ | 5.57 |  |  |  |  |  |  |  | - |
Granted |  |  | 150,500 |  |  | $ | 9.43 |  |  |  |  |  |  |  |  |
Exercised |  |  | (58,700 | ) |  | $ | 5.57 |  |  |  |  |  |  | $ | 306,574 |
Forfeited |  |  | (46,400 | ) |  | $ | 5.93 |  |  |  |  |  |  |  |  |
Options outstanding end of period (3) |  |  | 1,039,900 |  |  | $ | 6.12 |  |  |  | 4.8 |  |  | $ | 6,397,354 |
Options exercisable at September 30, 2024(4) |  |  | 386,000 |  |  | $ | 5.31 |  |  |  | 4.0 |  |  | $ | 2,684,482 |
(1) | Options with exercise prices ranging from $3.31 to $12.23.
(2) | Options with exercise prices ranging from $3.31 to $10.20.
(3) | Options with exercise prices ranging from $3.15 to $10.20.
(4) | Options with exercise prices ranging from $3.15 to $9.81.
(5) | The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price.
During the nine months ended September 30, 2025, the Company issued a total of 38,256 shares of its Common Stock under the 2003 Plan to its outside directors as compensation for serving on the Company’s Board. The Company recorded approximately $359,000 in compensation expenses (included in selling, general and administration (“SG&A”) expenses) in connection with the issuance of shares of its Common Stock to outside directors. During the nine months ended September 30, 2025, the Company issued an aggregate 40,208 shares of its Common Stock from cashless exercises of options for the purchase of 67,000 shares of the Company’s Common Stock ranging from $3.15 to $7.75 per share. Additionally, the Company issued an aggregate 21,700 shares of its Common Stock from cash exercises of options for the purchase of 21,700 shares of the Company’s Common Stock, at exercise prices ranging from $3.15 and $4.19 per share, resulting in proceeds of approximately $79,000. In connection with the Company’s sales of its Common Stock in May 2024 and December 2024, the Company issued warrants to certain underwriter, placement agents, and their designees to purchase up to an aggregate 188,038 shares of the Company’s Common Stock at exercise prices of $11.50 and $12.19 per share. These warrants remained outstanding as of September 30, 2025.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration